Nitric oxide and the proliferation of vascular smooth muscle cells

Cardiovascular Research

Volumn 43, Issue 3, 1999, Pages 580-594

  Jeremy, Jamie Y ^a   Rowe, Daniel ^a   Emsley, Alison M ^a   Newby, Andrew C ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM; CYCLINE; LINSIDOMINE; MITOGEN ACTIVATED PROTEIN KINASE; MOLSIDOMINE; MYC PROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; SUPEROXIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; GENE TRANSFER; HUMAN; INFLAMMATORY CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; TRANSGENIC ANIMAL; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; ARTERIOSCLEROSIS; CALCIUM; CELL DEATH; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH, VASCULAR; NEUTROPHIL INFILTRATION; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PLATELET AGGREGATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0033566951     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00171-6     Document Type: Review

References (208)

1. Furchgott R.F., Zawadski J.N. The obligatory role of endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
2. Griffith T.M., Edwards D.H., Lewis M.J., Newby A.C., Henderson A.H. The nature of endothelium derived vascular relaxant factor. Nature. 308:1984;645-647.
3. Bredt D.S., Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 63:1995;175-195.
4. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. Mol Med Today. December:1996.
5. Mehta D., Jeremy J.Y., Bryan A.J., Angelini G.D. Toward a solution for saphenous vein graft failure. Asian Pac Heart J. 6:1997;107-120.
6. Jeremy J.Y., Mehta D., Bryan A.J., Lewis D., Angelini G.D. Platelets and saphenous vein graft failure following coronary artery bypass graft surgery. Platelets. 8:1997;295-309.
7. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
8. Butler A.R., Fitney F.W., Williams D.L.H. Nitric oxide, nitrosium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci. 16:1995;18-22.
9. Darely-Usmar V., Wiseman H., Halliwell B. Nitrogen oxide and oxygen radicals: a question of balance. FEBS Lett. 369:1995;131-135.
10. Newby A.C., Fabunmi R.P., George S.J. Neointimal fibrosis in vascular pathologies: role of growth factors and metalloproteinases in vascular smooth muscle proliferation. Exp Nephrol. 3:1995;108-113.
11. Newby A.C., George S.J. Proliferation, migration, matrix turnover and death of smooth muscle cells in native coronary artery and vein graft atherosclerosis. Curr Opin Cardiol. 11:1996;574-582.
12. Lloyd-Jones D.M., Bloch K.D. The vascular biology of nitric oxide and and its role in atherosclerosis. Annu Rev Med. 47:1996;365-375.
13. Newby A.C., Zaltsman A.B. Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 41:1999;345-360.
14. Vanhoutte P.M., Perrault L.P., Vilaine J.P. Endothelial dysfunction and vascular disease. Rubanyi G.M., Dzau V.J. The endothelium in clinical practice. 1997;265-290 Marcel Dekker, New York.
15. Minor Jr R.L., Myer P.R., Guerra Jr R., Bates J.N., Harrison D.G. Diet induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 86:1990;2109-2116.
16. Harrison D.G., Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolaemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol. 75:1995;75B-81B.
17. 1. Arterioscler Thromb Vasc Biol. 15:1995;1255-1261.
18. Nunokawa Y., Tanaka S. Interferon inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun. 188:1992;409-415.
19. Bhagat K., Vallance P. Inducible nitric oxide synthase in the cardiovascular system. Heart. 75:1996;218-220.
20. Pomerantz K.B., Hajjar D.P., Levi R., Gross S.S. Cholesterol enrichment of arterial smooth muscle cells upregulates cytokine-induced nitric oxide synthesis. Biochem Biophys Res Commun. 191:1993;103-109.
21. Darley-Usmar V., White R. Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implication for cardiovascular disease. Exp Physiol. 82:1997;305-316.
22. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
23. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 266:1991;4244-4250.
24. Luoma J.S., Stralin P., Marklund S.L., et al. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human rabbit atherosclerotic lesions. Co-localization with epitopes characteristic of oxidised LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol. 18:1998;157-167.
25. Asahra T., Bauters C., Pastore C., et al. Local delivery of vascular endothelial growth factor accelerates reendothelialisation and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 91:1995;2793-2801.
26. Hamon M., Vallet B., Bauters C., et al. Long term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation. 90:1994;1357-1367.
27. Shimokawa H., Aahus L.L., Vanhoutte P.M. Porcine coronary arteries with regenerated endothelium have a reduced endothelium dependent responsiveness to aggregating platelets and serotonin. Circ Res. 61:1987;256-270.
28. Groves H.M., Kinlough-Rathbone R.L., Mustard J.F. Development of non-thombogenicity of injured artery despite inhibition of platelet adherence. Arteriosclerosis. 6:1986;189-196.
29. Joly G.A., Schini V.B., Vanhoutte P.M. Balloon injury and interleukin 1β induce nitric oxide synthase activity in rat carotid arteries. Circ Res. 71:1992;331-338.
30. Groves P.H., Banning A.P., Cheadle H.A., Penny W.J., Lewis M.J. The influence of exogenous nitric oxide on smooth muscle cell proliferation and intimal thickening in a porcine model of balloon angioplasty. Cardiovasc Res. 30:1995;87-96.
31. Cross K.S., El-Sanadiki M.N., Murray J.J. Endothelium-derived relaxing factor production is absent in vein grafts. Surg Forum. 38:1987;319-321.
32. Cross K.S., Davies M.G., El-Sanadiki M.N. Long term human vein graft contractility and morphology: a functional and histopathological study of retrieved coronary artery vein grafts. Br J Surg. 81:1994;699-705.
33. Ku D.D., Caulfield J.B., Kirklin J.K. Endothelium-dependent responses in long term human coronary artery bypass grafts. Circulation. 83:1991;403-411.
34. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelium growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 265:1993;H586-H592.
35. Davies M.G., Hagen P.-O. Pathobiology of intimal hyperplasia: a review. Eur J Vasc Surg. 9:1995;7-18.
36. Davies M.G., Berkowitz D.E., Hagen P.-O. Constitutive nitric oxide synthase is expressed and nitric oxide-mediated relaxation is preserved in retrieved human aortocoronary vein grafts. J Surg Res. 58:1995;732-738.
37. Jeremy J.Y., Izzat M.B., Mehta D., Bryan A.J., Angelini G.D. Nitric oxide synthase and cyclic nucleotide synthesis by porcine venous-arterial grafts. Ann Thorac Surg. 63:1997;470-476.
38. Jeremy J.Y., Dashwood M., Mehta D., et al. Nitric oxide synthase, prostacyclin and cyclic nucleotide production in externally stented porcine vein grafts. Atherosclerosis. 141:1998;297-305.
39. Dobrin P.B. Mechanical forces associated with the development of intimal hyperplasia with respect to vascular grafts. Dobrin P.B. Intimal hyperplasia. 1994;85-109 R.G. Landes, Austin, TX.
40. Evans L.V., Sumpio B.E. The role of mechanical forces in vitro in the development of intimal hyperplasia. Dobrin P.B. Intimal hyperplasia. 1994;112-138 R.H. Landes, Austin, TX.
41. Cayatte A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 14:1994;753-759.
42. Griesler H.P. The role of monocytes/macrophages in the formation of intimal hyperplasia. Dobrin P.B. Intimal hyperplasia. 1994;193-209 R.G. Landes, Austin, TX.
43. Angelini G.D., Bryan A.J., Williams H.M.J., Newby A.C. Distension promotes platelet and leucocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. A Cardiothorac Surg. 90:1990;433-4339.
44. Beckman J.S., Koppenol W.H. Nitric oxide superoxide and peroxynitrite. The good, the bad and the ugly. Am J Physiol. 271:1996;C1424-C1437.
45. Garg L.C., Hassid S. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
46. Kariya K., Kawahara Y., Araki S.-I., Fukuzaki H., Takai Y. Antiproliferative action of cyclic GMP elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis. 80:1989;143-147.
47. 2+ mobilization by cyclic AMP and GMP in rabbit aortic smooth muscle cells. Biochem J. 288:1992;527-532.
48. Mouradain D.L., Hutsell T.C., Keefer L.K. Nitric oxide (NO) donor molecules - effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 25:1995;674-678.
49. Southgate K.M., Newby A.C. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-GMP. Atherosclerosis. 82:1990;113-123.
50. Soyombo A.A., Angelini G.D., Newby A.C. Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J Thorac Cardiovasc Surg. 109:1995;2-12.
51. Garg L.C., Hassid S. Mechanisms of nitrosothiols-induced antimitogenesis in aortic smooth muscle cells. Eur J Pharmacol. 237:1993;249-259.
52. Giuffre A., Sarti P., D'Itri E., et al. On the mechanism of inhibition of cytochrome c oxidation by nitric oxide. J Biol Chem. 271:1996;33404-33408.
53. Sarkar R., Gordon D., Stanley J.C., Webb R.C. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 272:1997;H1810-H1818.
54. Sarkar R., Gordon D., Stanley J.C., Webb R.C. Dual cell cycle specific mechanism mediates the antimitogenic effects of nitric oxide in vascular smooth muscle cells. J Hypertens. 15:1997;275-283.
55. Cornwell T.T., Arnold E., Boerth N.J., Lincoln T.M. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP dependent kinase by cGMP. Am J Physiol. 267:1994;C1413-C1413.
56. Jeremy J.Y., Jackson C.L., Bryan A.J., Angelini G.D. Eicosanoids, fatty acids and restenosis following balloon angioplasty and vein graft surgery. Prostaglandins Leukotrienes Essent Fatty Acids. 54:1996;385-402.
57. Jeremy J.Y., Bryan A.J., Angelini G.D. Pathophysiology of vein graft disease following coronary artery bypass surgery. J Drug Dev Clin Prac. 8:1996;135-150.
58. 1. Exp Cell Res. 160:1985;117-125.
59. Liu Z., Wildhirt S.M., Weissmuller S., et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic intervention. Atherosclerosis. 140:1998;1-14.
60. Tomita H., Egashira K., Kubo-Inoue M., et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and cells. Arterioscler Thromb Vasc Biol. 18:1998;1456-1464.
61. Naruse K., Shimizu K., Muramatsu M., et al. Long-term inhibition of NO synthesis promotes atherosclerosis in hypercholesterolemic rabbit thoracic aorta. Arterioscler Thromb. 14:1994;746-752.
62. Nakamura M., Abe S., Tanaka M. Oral administration of NO synthase inhibitor failed to promote arteriosclerotic lesions in the aorta and coronary arteries of rabbits fed cholesterol. Atherosclerosis. 141:1998;53-60.
63. Aji W., Ravalli S., Szaboles M. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 95:1997;430-437.
64. Guo J.P., Panday M.M., Consigny P.C., Lefer A.M. Mechanism of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol. 38:1995;H1122-H1131.
65. Candipan R.C., Wang B.-Y., Buitrago R., Tsao P.S., Cooke J.P. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 16:1996;44-50.
66. Ohara Y., Peterson T.E., Harrison D.G. Dietary correction of hypercholesterolaemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 92:1995;898-903.
67. Cooke J.P., Singer A.H., Tsao P., et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
68. Cooke J.P., Tsao P.S. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb. 14:1994;653-655.
69. Hamon M., Vallet B., Bauters C., et al. Long term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium dependent acetylcholine-induced relaxation after arterial injury. Circulation. 90:1994;1357-1367.
70. McNamara D.B., Bedi B., Aurora H., et al. L-Arginine inhibits balloon catheter induced intimal hyperplasia. Biochem Biophys Res Commun. 1993;291-296.
71. Taguchi J., Abe J., Okazaki H., Takuwa Y., Kurokawa K. L. L-Arginine inhibits neointimal formation following balloon injury. Life Sci. 53:1993;PL387-PL392.
72. Seki J., Nishio M., Kato Y., Motoyama Y., Yoshida K. FK409, a new nitric oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis. 117:1995;97-106.
73. Schwarzbacher S.P., Lim T.T., Wang S. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation. 95:1997;1863-1869.
74. Numaguchi K., Egashira K., Takemoto M., et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodelling in rats. Hypertension. 26:1995;957-962.
75. Provost P., Tremblay J., Merhi Y. The anti-adhesive and anti-thrombotic effects of nitric oxide donor SIN-1 are combined with a decreased vasoconstriction in a porcine model of balloon angioplasty. Arterioscler Thromb Vasc Biol. 17:1997;1806-1812.
76. Lablanche J.-M., Grollier G., Lusson J.-R. The effects of direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study. Circulation. 95:1997;83-89.
77. Ooboshi H., Chu Y., Rios C.D., et al. Altered vascular function after adenovirus mediated overexpression of endothelial nitric oxide synthase. Am J Physiol. 42:1997;H265-H270.
78. Kullo I.J., Mozes G., Schwartz R.S., et al. Enhanced endothelium-dependent relaxations after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries. Hypertension. 30:1997;314-320.
79. Kullo I.J., Mozes G., Schwartz R.S., et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation. 96:1997;2254-2261.
80. Baker A.H., Mehta D., George S.J., Angelini G.D. Prevention of vein graft failure: potential applications for gene therapy. Cardiovasc Res. 35:1997;442-450.
81. Chen L.H., Daum G., Forough R., et al. Over expression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res. 82:1998;862-870.
82. Chen A.F.Y., O'Brien T., Katusic Z.S. Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system. Trends Pharmacol Sci. 19:1998;276-286.
83. von der Leyen H.E., Gibbons G.H., Morishita R., et al. Gene therapy inhibiting neointimal hyperplasia in vivo: transfer of endothelial nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
84. Janssens S., Flaherty D., Nong Z.X., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 97:1998;1274-1281.
85. Channon K.M., Blazing M.A., Shetty G.A., Potts K.E., George S.E. Adenoviral gene transfer of nitric oxide synthase: high level expression in human vascular cells. Cardiovasc Res. 32:1996;962-972.
86. Channon K.M., Qian H.S., Neplioueva V., et al. In vivo gene transfer of nitric oxide synthase enhances vasomotor function in carotid arteries from normal and cholesterol fed rabbits. Circulation. 98:1998;1905-1911.
87. Tsutsui M., Chen A.F.Y., O'Brien T., Crotty T.B., Katusic Z.S. Adventitial expression of recombinant eNOS gene restores NO production in arteries without endothelium. Arterioscler Thromb Vasc Biol. 18:1998;1231-1241.
88. Varenne O., Pislaru S., Gillijne H., et al. Local adenovirus mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 98:1998;919-926.
89. Rudic R.D., Shesely E.G., Maeda N., et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodelling. J Clin Invest. 101:1998;731-736.
90. Tzeng E., Shears L.L., Robbins P.D., et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med. 2:1996;211-225.
91. Tzeng E., Yoneyama T., Hatakeyama K., Shears L.L., Billiar T.R. Vascular inducible nitric oxide synthase gene therapy: requirement for guanosine triphosphate cyclohydrolase I. Surgery. 1996;315-321.
92. Shears L.L., Kawaharada N., Tzzeng E., et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 100:1997;2035-2042.
93. Shears L.L., Kibbe M.R., Murdock A.E.D., et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide gene transfer to rats and pigs in vivo. J Am Coll Surg. 187:1998;295-306.
94. Koglin J., Glysing Jensen T., Mudgett J.S., Russell M.E. Exacerbated transplant arteriosclerosis in inducible nitric oxide deficient mice. Circulation. 97:1998;2059-2065.
95. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 9:1995;726-735.
96. Pelech S.L., Sanghera J.S. Mitogen-activated protein kinases: versatile transducers for cell signaling. Trends Biochem Sci. 17:1992;233-238.
97. Pazin M.J., Williams L.T. Triggering signalling cascades by receptor tyrosine kinases. Trends Biochem Sci. 17:1992;374-378.
98. Barone M.V., Courtneidge S.A. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature. 378:1995;509-512.
99. Galaktionov K., Chen X., Beach D. Cdc25 cell cycle phosphatase as a target of c-myc. Nature. 382:1996;511-517.
100. Biro S., Fu X.-M., Yu Z.-X., Epstein S.E. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA. 90:1993;654-658.
101. Bennett M.R., Evan G.I., Newby A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-τ, heparin and cyclic nucleotide analogues and induces apoptosis. Circ Res. 74:1994;525-536.
102. Malarkey K., Belham C.M., Paul A., et al. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J. 309:1995;361-375.
103. Post G.R., Brown J.H. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J. 10:1996;741-749.
104. Marrero M.B., Schieffer B., Li B., et al. Role of janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II and platelet derived growth factor induced vascular smooth muscle cell proliferation. J Biol Chem. 272:1997;24684-224689.
105. Brandt K., Page S., Walli A.K., Neumeier D., Baeuerle P.A. Role of nuclear factor κB in atherogenesis. Exp Physiol. 82:1997;297-304.
106. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
107. Lew D.J., Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol. 8:1996;795-804.
108. Grana X., Reddy P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitor (CKIs). Oncogene. 11:1995;211-219.
109. Ajchenbaum F., Andok A., DeCaprio J.A., Griffin J.D. Independent regulation of cyclin-D type cyclin gene. J Biol Chem. 268:1993;4113-4119.
110. Won K.-A., Xiong Y., Beach D., Gilman M.Z. Growth regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA. 89:1992;9910-9914.
111. Cocks B.G., Vairo G., Bodrug S.E., Hamilton J.A. Suppression of growth factor induced CYL1 cyclin gene expression by antiproliferative agents. J Biol Chem. 267:1992;12307-12310.
112. Lallemain G., Lavoie J.N., Rivard N., Baldin V., Pouyssegur J. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene. 14:1997;1981-1990.
113. MAPK pathway. J Biol Chem. 271:1996;20608-20616.
114. Fukumoto S., Nishizawa Y., Hosoi M., et al. Protein kinase Cδ inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J Biol Chem. 272:1997;13816-13822.
115. Quelle D.E., Ashmun R.A., Shurtleff S.A., et al. Overexpression of mouse D-type cyclins accelerate G1 phase in rodent fibroblasts. Genes Dev. 7:1993;1559-1571.
116. Peeper D.S., Bernards R. Communication between the extracellular environment, cytoplasmic signalling cascades and the nuclear cell-cycle machinery. FEBS Lett. 410:1997;11-16.
117. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J. 308:1995;697-711.
118. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
119. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Gene Dev. 9:1995;1149-1163.
120. Milbourne E.A., Bygrave F.L. Do nitric oxide and cGMP play a role in calcium cycling? Cell Calcium. 18:1995;207-213.
121. Baran I. Calcium and cell cycle progression: possible effects of external perturbations on cell proliferation. Biophys J. 70:1996;1198-1213.
122. 3H]-thymidine incorporation by cultured human vascular smooth muscle cells. Br J Surg. 84:1997;325-330.
123. George S., Angelini G.D., Jeremy J.Y. Thapsigargin inhibits smooth muscle cell proliferation and intima formation. Arterioscler Thromb Vasc Biol. 17:1997;2500-2506.
124. Birkett S., Jeremy J.Y., Watts S., Angelini G.D., McArdle C. Time-dependent inhibition of intracellular calcium mobilisation by low concentrations of thapsigargin in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 33:1999;204-211.
125. Hardingham G.E., Chawla S., Johnson C.M., Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature. 385:1997;260-265.
126. Karaki H., Sato K., Ozaki H., Murakami K. Effects of sodium nitroprusside on cytosolic calcium level in vascular smooth muscle. Eur J Pharmacol. 156:1988;259-266.
127. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension. 20:1992;713-736.
128. Felbel J., Trockur B., Ecker T., Landgraf W., Hofmann F. Regulation of cytosolic calcium by cAMP and cGMP in freshly isolated smooth muscle cells from bovine trachea. J Biol Chem. 32:1988;16764-16771.
129. i in vascular smooth muscle cells by inhibition of the calcium current. Cell Calcium. 15:1994;122-131.
130. 2+ responses are differentially modulated by nitric oxide via activation of a cyclic GMP-dependent pathway. Mol Pharmacol. 48:1995;1068-1077.
131. 2+ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells. Eur J Pharmacol. 244:1993;269-275.
132. Appel R.G. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol. 262:1992;F911-F918.
133. 2+ in rat aortic smooth muscle cells. Am J Physiol. 43:1998;H1613-H1619.
134. Yu S.-M., Hung M.-M., Lin C.-C. cGMP elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation. 95:1997;1269-1277.
135. Dhaunsi G.S., Matthews C., Kaur K., Hassid A. NO increases protein tyrosine phosphatase activity in smooth muscle cells: relationship to antimitogenesis. Am J Physiol. 272:1997;H1342-H1349.
136. Bennett M.R., Anglin S., McEwan J.R., et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligonucleotides. J Clin Invest. 93:1994;820-828.
137. Bennett M.R., Evan G.I., Newby A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-τ, heparin and cyclic nucleotide analogues and induces apoptosis. Circ Res. 74:1994;525-536.
138. 21Sd1i/Cip1/Waf1 by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem. 272:1997;10050-10057.
139. Kwon N.S., Stuehr D.J., Nathan C.F. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med. 174:1991;761-767.
140. Lepoivre M., Fieschi F., Coves J.J., Thelander L., Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun. 179:1991;442-448.
141. Nathan C., Xie Q.W. Regulation of biosynthesis of nitric oxide. J Biol Chem. 269:1994;13725-13728.
142. Bennett M. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res. 41:1999;361-368.
143. Campbell J.H., Campbell G.R. Endothelial cell influences on vascular smooth muscle phenotype. Ann Rev Physiol. 48:1986;295-306.
144. Schwartz S., Campbell G., Campbell J. Replication of smooth muscle cells in vascular disease. Circ Res. 82:1986;113-123.
145. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
146. Kockx M.M. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol fed-rabbits. Atherosclerosis. 120:1996;115-124.
147. Isner J.M., Kearney M., Bortman S., Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 91:1995;2703-2711.
148. Haunsetter A., Izumo S. Apoptosis: basic mechanisms and implication for cardiovascular disease. Circ Res. 82:1998;1111-1129.
149. Pollman M.J., Hall J.L., Mann M.J., Zhang L., Gibbons G.H. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nature Med. 4:1998;222-227.
150. Bennett M.R., Boyle J.J. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 138:1998;3-9.
151. Fukuo K., Inoue T., Morimoto S., et al. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells: a possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest. 95:1995;669-676.
152. Perlman H., Mallard L., Krasinski K., Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation. 95:1997;981-987.
153. Geng Y.-J., Wu Q., Muszynski M., Hansson G.K., Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumour necrosis factor-α and interleukin 1β Arterioscler Thromb Vasc Biol. 15:1995;18-27.
154. Messmer U.K., Ankarcrona M., Nicotera P., Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Lett. 355:1994;23-26.
155. Sarih M., Souvannavong V., Adam A. Nitric oxide synthase induces macrophage death by apoptosis. Biochem Biophys Res Commun. 191:1993;503-508.
156. Abedi H., Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 30:1995;544-556.
157. Goligorsky M.S., Noiri E., Peresleni T., Hu Y. Role of nitric oxide in cell adhesion and locomotion. Exp Nephrol. 4:1996;314-321.
158. Dubey R.K., Jackson E.K., Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. J Clin Invest. 96:1995;141-149.
159. Rizvi M.A.D., Myers P.R. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol. 29:1997;1779-1789.
160. Trachtman H., Futterweit S., Garg P., Reddy K., Singhal P.C. Nitric oxide stimulates the activity of a 72 kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 218:1996;704-708.
161. Myers P.R., Tanner M.A. Vascular endothelial cell regulation of extracellular matrix collagen - role of nitric oxide. Arterioscler Thromb Vasc Biol. 18:1998;717-722.
162. Koo E.W.Y., Gotlieb A.I. Endothelial stimulation of intimal cell proliferation in a porcine aortic organ culture. Am J Pathol. 134:1989;497-503.
163. Angelini G.D., Soyombo A.A., Newby A.C. Smooth muscle cell proliferation in response to injury in an organ culture of human saphenous vein. Eur J Vasc Surg. 5:1991;5-12.
164. Hansson G.K., Geng Y., Holm J. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med. 180:1994;733-738.
165. Kourembanas S., McQuillan L.P., Leung G.K., Faller D.V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 92:1993;99-104.
166. Force T. Mechanisms of endothelin-induced mitogenesis in vascular smooth muscle. Highsmith R.E. Endothelin: molecular biology, physiology and pathology. 1998;121-166 Humana Press, Totowa, NJ.
167. Sachinidis A., Locher R., Hoppe J., Vetter W. The platelet derived growth factor isomers PDGF-AA and PDGF-BB induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS Lett. 275:1990;905-908.
168. A receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation. 95:1997;240-244.
169. Sueeshi K., Takeshita A. Important role of tissue angiotensin converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 99:1997;278-287.
170. Arnal J.-F., Yamin J., Dockery S., Harrison D.G. Regulation of endothelial nitric oxide synthase mRNA, protein and activity during cell growth. Am J Physiol. 267:1994;C1381-C1388.
171. Tzeng E., Kim Y.M., Pitt B.R., et al. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery. 122:1997;255-263.
172. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 267:1992;10931-10934.
173. Van Der Zee R., Morohara T., Luo Z., et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 95:1997;1030-1037.
174. Morbidelli L., Chang C.-H., Douglas J.G., et al. Nitric oxide mediates mitogenic effect of VEGF in coronary venular endothelium. Am J Physiol. 270:1996;H411-H415.
175. Noiri E., Lee E., Testa J., et al. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol. 43:1998;C236-C244.
176. Ziche M., Morbidelli L., Masini E., et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 94:1994;2036-2044.
177. Ziche M., Morbidelli L., Parenti A., et al. Substance P increases cyclic GMP levels on coronary postcapillary venular endothelial cells. Life Sci. 53:1993;1105-1112.
178. Ziche M., Morbidelli L., Masini E., et al. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun. 192:1993;1198-1203.
179. Leibovich S.J., Polverini P.J., Fong T.W., Harlow L.A., Koch A.E. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide synthase dependent effector mechanism. Proc Natl Acad Sci USA. 91:1994;4190-4194.
180. Laitinen M., Zachary I., Breier G., et al. VEGF transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 8:1997;1737-1744.
181. Lefer Am. Nitric oxide: Nature's naturally occurring leukocyte inhibitor. Circulation. 95:1997;553-554.
182. Radomski M.W., Palmer R.M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1987;1057-1058.
183. Bloom A.L., Thomas D.P. Haemostasis and thrombosis. 1987;90-100 Churchill Livingstone, Edinburgh.
184. Jeremy J.Y., Nystrom M.L., Barradas M.A., Mikhailidis D.P. Eicosanoids and septicaemia. Prostaglandins Leukotrienes Essent Fatty Acids. 50:1994;287-297.
185. Ott I., Neumann F.-J., Gawaz M., Schmitt M., Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 94:1996;1239-1246.
186. Entman M.L., Ballatyne C.A. Association of neutrophils with platelet aggregates in unstable angina; should we alter therapy? Circulation. 94:1996;1206-1208.
187. Demiryurek A.T., Cakier I., Kanzik I. Peroxynitrite: a putative cytotoxin. Pharmacol Toxicol. 82:1998;113-117.
188. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
189. 2+ signaling in vascular endothelial cells. Am J Physiol. 14:1996;L954-L961.
190. - in vascular smooth muscle cells. Circ Res. 77:1995;29-36.
191. Tarpey M.M., Beckman J.S., Ischiropoulos H., Gore J.Z., Brock T.A. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis. FEBS Lett. 364:1995;314-318.
192. Shin J.T., Barbeito L., MacMIllan Crow L.A., Beckman J.S., Thompson J.A. Acidic fibroblast growth factor enhances peroxynitrite induced apoptosis in primary murine fibroblasts. Arch Biochem Biophys. 335:1996;32-41.
193. Emsley A.M., Plane F., Jackson C.L., Miller A.L., Jeremy J.Y. Oxidant stress, nitric oxide and transition metals in homocysteinaemic angiopathy: novel mechanisms. Vasc Dis. 1:1998;1-5.
194. Emsley A., Jeremy J.Y., Gomes G., Angelini G.D., Plane F. Effects of copper and homocysteine on endothelium-dependent relaxation in the rat isolated aorta. Br J Pharmacol. 126:1999;1034-1040.
195. Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocysteine induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 58:1976;731-741.
196. Harker L.A., Harlan J.M., Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 53:1983;731-739.
197. Lentz S.R., Sobey C.G., Plegors D.J., et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 98:1996;24-29.
198. Rolland P.H., Friggi A., Barlatier A., et al. Hyperhomocysteinemia induced vascular damage in the minipig. Captopril hydrochlorothiazide combination prevents elastic alterations. Circulation. 91:1995;1161-1174.
199. Tsai J.-C., Perella M.A., Yoshizumi M., et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 91:1994;6373-6373.
200. Tsai J.-C., Wang H., Perella M.A., et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 97:1996;146-153.
201. Wang H., Yoshimuzi M., Lai K., et al. Inhibition of growth and p21ras in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 272:1997;25380-25385.
202. Tang L.L., Mamotte C.D.S., Bockxmeer V., Taylor R.R. The effects of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis. 136:1998;169-173.
203. Dalton M.J., Gadsdon P.F., Wrenn R.W., Rosenquist T.H. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C and the induction of and c-fos and c-myb in smooth muscle cells. FASEB J. 11:1997;703-711.
204. Lubec B., Labudova O., Hoeger H., et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation. 94:1996;2620-2625.
205. Majors A., Ehrhart A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 17:1997;2074-2081.
206. Tyagi S.C. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol. 43:1998;C396-C405.
207. Jourdheuil Rahmani D., Rolland P.H., Rosset E., Branchereau A., Garcon D. Homocysteine induces synthesis and secretion of serine elastase in human arterial smooth muscle cells. Cardiovasc Res. 34:1997;597-602.
208. Loscalzo J. The oxidant stress of hyperhomocysteineamia. J Clin Invest. 98:1996;5-7.